{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T19:26:22Z","timestamp":1783106782219,"version":"3.54.6"},"reference-count":31,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina de Familia. SEMERGEN"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.semerg.2026.102759","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T20:33:22Z","timestamp":1777581202000},"page":"102759","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Systematic review and meta-analysis on the safety and efficacy of obicetrapib combination therapy in dyslipidemia"],"prefix":"10.1016","volume":"52","author":[{"given":"M.","family":"Nawaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Hassan Zafar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Ibrahim Smeak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Rab Nawaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Timsina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Andleeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Waheed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Hammad Arif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Ahmad Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semerg.2026.102759_bib0160","first-page":"203","article-title":"Management of atherogenic dyslipidemia in the primary care setting in Spain","volume":"31","author":"D\u00edaz Rodr\u00edguez","year":"2019","journal-title":"Clin Investig Arterioscler"},{"key":"10.1016\/j.semerg.2026.102759_bib0165","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary","volume":"73","author":"Grundy","year":"2019","journal-title":"JACC"},{"key":"10.1016\/j.semerg.2026.102759_bib0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2024.122823","article-title":"Role of CETP, PCSK-9, and CYP7-alpha in cholesterol metabolism: potential targets for natural products in managing hypercholesterolemia","volume":"351","author":"Aguchem","year":"2024","journal-title":"Life Sci"},{"key":"10.1016\/j.semerg.2026.102759_bib0175","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1093\/cvr\/cvab350","article-title":"Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents?","volume":"118","author":"Nurmohamed","year":"2022","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.semerg.2026.102759_bib0180","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s11883-024-01231-5","article-title":"Obicetrapib \u2013 the rebirth of CETP inhibitors?","volume":"26","author":"Chang","year":"2024","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.semerg.2026.102759_bib0185","series-title":"Why combination lipid-lowering therapy should be considered early in the treatment of elevated LDL-C for CV risk reduction","first-page":"6","author":"Varughese","year":"2022"},{"key":"10.1016\/j.semerg.2026.102759_bib0190","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.jacl.2024.12.016","article-title":"Lipid-lowering efficacy of obicetrapib: a comprehensive systematic review and meta-analysis","volume":"19","author":"Masson","year":"2025","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.semerg.2026.102759_bib0195","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11883-023-01184-1","article-title":"Obicetrapib: reversing the tide of CETP inhibitor disappointments","volume":"26","author":"Kastelein","year":"2024","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.semerg.2026.102759_bib0200","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.semerg.2026.102759_bib0205","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.semerg.2026.102759_bib0210","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.semerg.2026.102759_bib0215","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.jacl.2023.05.098","article-title":"Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: a randomized phase 2 trial","volume":"17","author":"Ballantyne","year":"2023","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.semerg.2026.102759_bib0220","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S0140-6736(15)60158-1","article-title":"Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial","volume":"386","author":"Hovingh","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.semerg.2026.102759_bib0225","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0140-6736(25)00721-4","article-title":"Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"405","author":"Sarraju","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.semerg.2026.102759_bib0230","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1038\/s41591-022-01936-7","article-title":"Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial","volume":"28","author":"Nicholls","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.semerg.2026.102759_bib0235","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.5551\/jat.64828","article-title":"Obicetrapib as an adjunct to stable statin therapy in Japanese subjects: results from a randomized phase 2 trial","volume":"31","author":"Harada-Shiba","year":"2024","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.semerg.2026.102759_bib0240","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.semerg.2026.102759_bib0245","series-title":"Endotext","article-title":"Guidelines for the management of high blood cholesterol","author":"Feingold","year":"2000"},{"key":"10.1016\/j.semerg.2026.102759_bib0250","doi-asserted-by":"crossref","DOI":"10.1002\/clc.70138","article-title":"Lipid-lowering effect and safety of ezetimibe and atorvastatin 5mg in patients with primary hypercholesterolemia or mixed dyslipidemia: a randomized, double-blind, parallel, multicenter, phase 3 clinical trial","volume":"48","author":"Ki","year":"2025","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.semerg.2026.102759_bib0255","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)","volume":"41","author":"Mach","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.semerg.2026.102759_bib0260","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1016\/S0140-6736(25)00827-X","article-title":"Obicetrapib\u2013ezetimibe combination therapy for patients with atherosclerotic cardiovascular disease","volume":"405","author":"Lee","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.semerg.2026.102759_bib0265","article-title":"Lipoprotein(a): emerging insights and therapeutics","volume":"18","author":"Kaur","year":"2024","journal-title":"Am J Prevent Cardiol"},{"key":"10.1016\/j.semerg.2026.102759_bib0270","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1373\/jalm.2016.021006","article-title":"Lipoprotein biomarkers and risk of cardiovascular disease: a laboratory medicine best practices (LMBP) systematic review","volume":"1","author":"Sandhu","year":"2016","journal-title":"J Appl Lab Med"},{"key":"10.1016\/j.semerg.2026.102759_bib0275","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1093\/eurheartj\/ehx163","article-title":"Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies","volume":"38","author":"Madsen","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.semerg.2026.102759_bib0280","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1056\/NEJM199011013231803","article-title":"Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation","volume":"323","author":"Inazu","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semerg.2026.102759_bib0285","doi-asserted-by":"crossref","first-page":"37","DOI":"10.4137\/CMC.S32667","article-title":"CETP inhibition: past failures and future hopes","volume":"10","author":"Kosmas","year":"2016","journal-title":"Clin Med Insights Cardiol"},{"key":"10.1016\/j.semerg.2026.102759_bib0290","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1001\/jamacardio.2021.3728","article-title":"Long-term benefits and harms associated with genetic cholesteryl ester transfer protein deficiency in the general population","volume":"7","author":"Nordestgaard","year":"2022","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.semerg.2026.102759_bib0295","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.semerg.2021.10.007","article-title":"Posicionamiento SEMERGEN en el abordaje de la insuficiencia card\u00edaca cr\u00f3nica en atenci\u00f3n primaria","volume":"48","author":"Castillo Moraga","year":"2022","journal-title":"Med Fam SEMERGEN"},{"key":"10.1016\/j.semerg.2026.102759_bib0300","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.5551\/jat.64988","article-title":"Early, intensive and persistent lipid-lowering therapy for secondary prevention of acute coronary syndrome","volume":"31","author":"Okada","year":"2024","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.semerg.2026.102759_bib0305","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1161\/CIRCRESAHA.117.311978","article-title":"Trials and tribulations of CETP inhibitors","volume":"122","author":"Tall","year":"2018","journal-title":"Circ Res"},{"key":"10.1016\/j.semerg.2026.102759_bib0310","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1161\/ATV.0000000000000073","article-title":"Statin safety and associated adverse events: a scientific statement from the American Heart Association","volume":"39","author":"Newman","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"}],"container-title":["Medicina de Familia. SEMERGEN"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1138359326000766?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1138359326000766?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T19:06:23Z","timestamp":1783105583000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1138359326000766"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1138359326000766"],"URL":"https:\/\/doi.org\/10.1016\/j.semerg.2026.102759","relation":{},"ISSN":["1138-3593"],"issn-type":[{"value":"1138-3593","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systematic review and meta-analysis on the safety and efficacy of obicetrapib combination therapy in dyslipidemia","name":"articletitle","label":"Article Title"},{"value":"Medicina de Familia. SEMERGEN","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semerg.2026.102759","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Sociedad Espa\u00f1ola de M\u00e9dicos de Atenci\u00f3n Primaria (SEMERGEN). Published by Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102759"}}